Leonteq AG (0QNE)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 20.50 |
|---|---|
| 52-week range | 10.32 – 22.25 |
| Return, 1 month / 3 months | +3.4% / +16.9% |
| Return, 1 year / 3 years | +31.6% / −45.1% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 44.1% |
| Worst drawdown (1 year) | -31.9% |
| Average daily value traded | 0.09M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Leonteq is a Swiss financial technology firm based in Zurich that builds and operates a platform for structured investment products and insurance-linked solutions. Banks, asset managers and insurance companies use its technology and services to design, issue and manage products for their own clients. Leonteq also offers its own structured products and provides risk and balance sheet solutions, serving financial institutions and investors across several markets in Europe and beyond.
On this site Leonteq AG appears as a stock on the London Stock Exchange (UK), code 0QNE, with prices in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Leonteq AG (0QNE) trades on the London Stock Exchange in UK. It last closed at GBP 20.50 on 27 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 1,008 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 31.6% and over the last three months it rose 16.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 24.6% | ||
| From 52-week high | -5.6% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 16.9% | ||
| 6-month return | 36.5% | ||
| 12-month return, skipping the last month | 27.2% | ||
| Stability (higher is calmer) | 40 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 44.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -31.9% | ||
| Liquidity | 29 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.09M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.7% |
|---|---|
| 1 month | +3.4% |
| 3 months | +16.9% |
| 6 months | +36.5% |
| 1 year | +31.6% |
| 3 years | −45.1% |
| 5 years | −66.4% |
Signals
| 50-day / 200-day average | 20.39 / 16.45 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.40 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Mar 2025 | GBX 0.0150 |
| 3 Apr 2024 | GBX 0.0050 |
| 3 Apr 2023 | GBX 0.0200 |
| 4 Apr 2022 | GBX 0.0150 |
| 6 Apr 2021 | GBX 0.0038 |
| 2 Apr 2020 | GBX 0.0025 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.